Our Company Features
Most advanced adhesion and delivery system
Proprietary patch technology optimizes drug delivery through the skin.
Anti-inflammatory oral solution delivers individualized dosing
Precision dosing in high risk patients.
The only liquid ready-to-use analgesic formulated in a proprietary delivery system
Delivers fast and long lasting migraine relief.
About Us
Leader in non-opioid pain management products
Scilex Holding Company (Nasdaq: SCLX) is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and becoming the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products that maximize quality of life.
About Us
Leader in non-opioid pain management products
Scilex Holding Company (Nasdaq: SCLX) is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life.
Product Portfolio
OPTIMIZE QUALITY OF LIFE THROUGH PHARMACEUTICALS
Testimonals
Topical Delivery Systems Effectively Transport Analgesics to Areas of Localized Pain via Direct Diffusion
Pain Freedom With Celecoxib Oral Solution, Ubrogepant, and Rimegepant Through 4 Hours Postdose
Corporate Presentation
Scilex Holding Company Corporate Presentation
Download here »
November 6, 2024
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali
Read More »October 30, 2024
Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4%, a Next-Generation, Triple-Strength Formulation of ZTlido, for the Treatment of Chronic Neck Pain Associated with Muscle Spasms
Read More »Do you have any questions? Lets talk!
650-516-4310